# Tirzepatide dosage & reconstitution (5 mg vial)

Tirzepatide dosage: calculations for a 5 mg vial use the same amounts described in the literature. Adding 1 mL of bacteriostatic water produces 5 mg/mL, so each U-100 unit contains 50 mcg.

- **Vial contents:** 5 mg Tirzepatide
- **Final volume:** 1 mL
- **Concentration:** 5 mg/mL
- **One U-100 unit:** 50 mcg in 0.01 mL

## Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing

### Standard Weekly Escalation Schedule (1 mL = ~5 mg/mL)

| Study phase | Weekly dose | Units per injection (mL) |
|---|---|---|
| Weeks 1 to 4 | 2.5 mg (2500 mcg) | 50 units (0.50 mL) |
| Weeks 5 to 8 | 5 mg (5000 mcg) | 100 units (1.00 mL) |
| Weeks 9 to 12 | 7.5 mg (7500 mcg) | Split: 2 × 75 units (0.75 mL each) |
| Weeks 13 to 16 | 10 mg (10000 mcg) | Split: 2 × 100 units (1.00 mL each) |
| Weeks 17 to 20 | 12.5 mg (12500 mcg) | Split: 3 × 83.3 units (0.83 mL each) |
| Weeks 21+ | 15 mg (15000 mcg) | Split: 3 × 100 units (1.00 mL each) |

Frequency: Once weekly, subcutaneously, at a consistent time.

### Reconstitution Steps

1. Draw 1 mL of bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid shaking to prevent foaming.
3. Gently swirl or roll until fully dissolved (clear solution).
4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

## U-100 Conversion Table

| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 50 injections |
| 5 | 0.05 mL | 250 mcg | 20 injections |
| 10 | 0.10 mL | 500 mcg | 10 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 5 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 3 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 2 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 1 injection |

## Supplies Needed

**Tirzepatide vials (5 mg each)**
- Standard Weekly Escalation Schedule, 12 weeks: Minimum 12 vials (60 mg required).
- Standard Weekly Escalation Schedule, 24 weeks: Minimum 42 vials (210 mg required).

**U-100 syringes (1 mL)**
- Standard Weekly Escalation Schedule, 12 weeks: 16 new syringes for 12 injections.
- Standard Weekly Escalation Schedule, 24 weeks: 48 new syringes for 24 injections.

**Bacteriostatic water**
- Standard Weekly Escalation Schedule, 12 weeks: 12 mL total (1 mL per vial) → 4 × 3 mL vials.
- Standard Weekly Escalation Schedule, 24 weeks: 42 mL total (1 mL per vial) → 14 × 3 mL vials.

**Alcohol swabs**
- Standard Weekly Escalation Schedule, 12 weeks: 32 minimum; one box of 100 covers the calculation.
- Standard Weekly Escalation Schedule, 24 weeks: 96 minimum; one box of 100 covers the calculation.

## Storage Instructions

- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.

## How This Works

Tirzepatide represents a revolutionary advance as the first dual agonist of the GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 receptors. This 39-amino-acid synthetic peptide (MW: 4813 Da) integrates: Molecular Architecture: Base sequence: native human GIP (amino acids 1-30) Ala² modification: substitution with 2-aminoisobutyric acid (DPP-4 stability) C20 acyl side chain at Lys²⁰ with gamma-Glu-OEG spacer Albumin binding: >99% (extended half-life) Synergistic Dual Mechanisms: GIP Pathway (GIP-R Receptor): Predominant expression: pancreatic β cells, adipocytes, brain Insulin secretion potentiation: 50-70% higher than GLP-1 alone Adipocyte lipolysis: activation via cAMP/PKA Neuroprotection: hippocampal and cortical expression GLP-1 Pathway (GLP-1R Receptor): Glucose-dependent insulin secretion Central appetite suppression (arcuate/paraventricular nucleus) Gastric emptying delay (70-80%) Glucagon secretion inhibition Distinctive Pharmacokinetics: SC Bioavailability: 80% Tmax: 8-72 hours (broad peak) Half-life: ~5 days (120 hours) Steady state: 4 weeks Elimination: proteolytic degradation + minimal renal excretion

## Research FAQ

**Why does tirzepatide outperform single GLP-1 agonists?** A: Dual GIP/GLP-1 activation produces a synergistic effect: GIP enhances insulin secretion and lipolysis, while GLP-1 maximizes satiety and glycemic control, resulting in 30-40% superior effects.
**Q: Is it appropriate for fatty liver disease models?** A: Excellent for NAFLD/NASH: reduces steatosis (50%), improves ALT/AST levels (35%), and reduces hepatic fibrosis as determined by histology (Hartman et al., 2020).
**Optimal protocol for body composition studies?** A: DEXA or baseline MRI and at weeks 4, 8, 12, and 16; abdominal circumference measurements every two weeks; plasma metabolomic analysis every 4 weeks.
**P: Interactions with basal insulin research?** A: Compatible and synergistic; it allows for a reduction in insulin dosage by 40-50% while maintaining glycemic control, with fewer episodes of hypoglycemia.

## References

1. Jastreboff AM et al. N Engl J Med 2022;387(3):205-216. PMID 35658024
2. Frias JP, et al. (2021) “Tirzepatide Versus Semaglutide Once Weekly in Patients With Type 2 Diabetes” – The New England Journal of Medicine 385(6):503-515. [PubMed: 34170647]
3. Rosenstock J, et al. (2021) “Efficacy and safety of once-weekly tirzepatide” – Lancet 398(10295):143-155. [PubMed: 34186022]
4. Cai HY, et al. (2022) “Dual GIP/GLP-1 receptor agonist in Alzheimer’s disease models” – Neuropharmacology 210:109023. [PubMed: 35364126]
5. Hartman ML, et al. (2020) “Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis” – Hepatology 71(4):1222-1232. [PubMed: 31625611]
6. Eli Lilly Research (2022) “Tirzepatide: A novel dual GIP and GLP-1 receptor agonist” – Cell Metabolism 33(7):1284-1295.

---
Source: https://protocolopeptidos.com/en/compuestos/tirzepatide-5mg · Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.